Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.

Published

Journal Article

Anamorelin hydrochloride is an orally active ghrelin receptor agonist in development by Helsinn, for the treatment of non-small-cell lung cancer (NSCLC) cachexia. In preclinical and clinical studies, the potent affinity of anamorelin for the ghrelin receptor is associated with significant appetite-enhancing activity and resultant improvements in body weight, lean body mass, and handgrip strength compared with placebo. The accompanying stimulatory effects on growth hormone and IGF-1 are not associated with tumor growth, and overall survival in patients with cancer is not compromised. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. The findings of ongoing Phase III studies are needed to confirm the significant potential of anamorelin to treat NSCLC cachexia.

Full Text

Cited Authors

  • Currow, DC; Abernethy, AP

Published Date

  • April 2014

Published In

Volume / Issue

  • 10 / 5

Start / End Page

  • 789 - 802

PubMed ID

  • 24472001

Pubmed Central ID

  • 24472001

Electronic International Standard Serial Number (EISSN)

  • 1744-8301

International Standard Serial Number (ISSN)

  • 1479-6694

Digital Object Identifier (DOI)

  • 10.2217/fon.14.14

Language

  • eng